press release

NovoSeven® recommended for approval for the treatment of severe postpartum haemorrhage by the European Medicines Agency

Heavy bleeding after giving birth is globally a leading cause of death in new mothers¹

Bagsværd, Denmark, 22 April 2022 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an extension of the NovoSeven® (eptacog alfa) label to include treatment of women suffering from severe haemorrhage after giving birth, when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding.

Severe postpartum haemorrhage (PPH) is when a woman suffers from blood loss of more than 1,500 mL within 24 hours after giving birth.² It accounts for 1 in 4 maternal deaths globally, making it a significant contributor to maternal morbidity.¹

The positive opinion is based on data from a prospective randomised clinical trial in women with severe PPH where uterotonics had failed to control the bleeding. In the primary analysis, fewer women in the NovoSeven® arm (21 vs 35) underwent additional medical procedures, such as ligation and embolisation, to stop the bleeding, corresponding to a 40% relative reduction in risk compared to standard of care.³

“Postpartum haemorrhage is a serious and dangerous condition,” said Martin Lange, executive vice president and head of Development at Novo Nordisk. “Reducing maternal mortality is a United Nations Sustainable Development Target and something that is very important to us at Novo Nordisk. We’re pleased with the potential of NovoSeven® being able to help mothers who may need it.”

Novo Nordisk expects a final approval by the European Commission within approximately two months.

About postpartum haemorrhage
Postpartum haemorrhage (PPH) is an emergency in childbirth and the most common form of major childbirth-related haemorrhage. Severe PPH is defined by blood loss greater than 1,500 mL, approximately 25% of a women’s total blood volume, within 24 hours of giving birth,
regardless of the route of delivery (vaginal or caesarean). The signs and symptoms of severe PPH include dizziness, shaking, increased heartbeat and confusion. The global incidences of PPH and severe PPH are estimated to be 6-11% and 1-3% of all births, respectively, with substantial variations across regions.

About NovoSeven® (eptacog alfa)
The active substance in NovoSeven®, eptacog alfa, is almost identical to a human protein called factor VII (FVII) and works in the same way. In the body, FVII activates another factor called factor X (FX), which starts the blood clotting process. By activating FX, NovoSeven® can give temporary control of the bleeding episodes. First approved in the EU in 1996, NovoSeven® is indicated in Europe for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in patients with congenital haemophilia with inhibitors, acquired haemophilia and some other rare bleeding disorders.

About NovoSeven® in severe postpartum haemorrhage
NovoSeven® has been evaluated in severe PPH across a multicentre, open label clinical trial assessing 84 women with severe PPH in whom uterotonics (sulprostone) had failed. In the trial, patients were randomised either to treatment with a single dose of 60 µg/kg of NovoSeven® combined with standard of care (N=42) or to standard of care alone (N=42). Results indicated that fewer women in the NovoSeven® arm (21 vs 35) underwent an invasive procedure to stop the bleeding, corresponding to a 40% relative reduction in risk for the NovoSeven® arm compared to standard of care alone. In the trial, there were two non-deadly venous thromboembolic events in NovoSeven® treated patients. Both women recovered following anticoagulant treatment.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further information
Media:
Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com
Natalia Salomao Abrahao (US) +1-8483041027 niaa@novonordisk.com

Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
References


3 Data on file [to be published upon approval].
